Form 4 Filing for Charles W. Newton at Coherus Oncology, Inc.

Charles W. Newton, a director at Coherus Oncology, Inc. (CHRS), acquired 30,000 shares of Common Stock and 60,000 Stock Options on June 5, 2026. The Common Stock acquisition, valued at $0 per share, is related to restricted stock units that will vest on June 3, 2027, subject to continued service. The Stock Options, also acquired at $0 per share, are for the right to buy Common Stock and will vest on June 3, 2027, contingent upon continued service. The underlying shares for the options are 60,000, with an exercise price of $1.45 and an expiration date of June 5, 2036. Mr. Newton directly owns these securities post-transaction.